Summary : Genmab Initiates a Phase I / II Study of Zalutumumab in Combination With Radiotherapy for the Treatment of Advanced Head and Neck Cancer. patients who are ineligible for platinum based chemotherapy. enrolled and treated at this level. of zalutumumab and will be followed for a total of 2 years. relation to actual results , unless this is required by law .